Viridian Therapeutics Reports Increase in Q1 2025 G&A Expenses; Strong Cash Position of $636.6 Million

Viridian Therapeutics Inc., a biotechnology company focused on developing treatments for serious and rare diseases, reported its financial results for the first quarter ended March 31, 2025. The company highlighted a 14% increase in general and administrative expenses, totaling $17.1 million compared to $15.0 million in the same period of 2024. The rise in expenses was attributed to increased costs associated with preparatory commercial activities for the upcoming launch of veligrotug, alongside higher legal, accounting, and professional service expenses to support the expanding organization. As of March 31, 2025, Viridian had 100,258,627 shares of common stock outstanding on an as-converted basis, which includes 81,589,427 shares of common stock and 18,669,200 shares of common stock issuable upon the conversion of Series A and Series B preferred stock. The company maintains a strong cash position of $636.6 million, which is expected to support its operations into the second half of 2027. Significant business updates include the planned submission of a Biologics License Application (BLA) for veligrotug in the second half of 2025, with potential for a U.S. launch in 2026, and ongoing phase 3 clinical trials for VRDN-003 aimed at treating thyroid eye disease, with topline data anticipated in the first half of 2026. Additionally, Viridian plans to submit an Investigational New Drug (IND) application for VRDN-008 by the end of 2025. The company also announced the appointment of Jeff Ajer to its board of directors, bringing over 25 years of experience in commercialization for rare diseases and specialty medicines. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-113291), on May 06, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here